1 hour ago
2
James Brumley, The Motley Fool
Tue, March 31, 2026 astatine 11:28 AM CDT 3 min read
Drugmaker Agios Pharmaceuticals (NASDAQ: AGIO) is positioning to triumph the FDA's support of its mitapivat arsenic a attraction for sickle compartment illness sooner than investors whitethorn person been expecting.
That's the overarching takeaway from this morning's property merchandise anyway. As it explains, Agios' caller gathering with the U.S. Food and Drug Administration laid the groundwork for the "submission of a connection for a confirmatory objective proceedings to enactment U.S. accelerated support of mitapivat." The company's already submitted the connection for this abbreviated trial, successful fact, and expects to taxable its petition for accelerated afloat support to the FDA wrong the adjacent fewer months.
Will AI make the world's archetypal trillionaire? Our squad conscionable released a study connected the 1 little-known company, called an "Indispensable Monopoly" providing the captious exertion Nvidia and Intel some need. Continue »
Agios Pharmaceuticals' oral pyruvate kinase (PK) activator mitapivat is proving to beryllium a susceptible multipurpose therapy. Already approved to dainty respective forms of anemia, the cause has besides performed good successful the company's alleged RISE UP trials arsenic a attraction for sickle compartment illness ... a comparatively uncommon illness with a constricted fig of effectual attraction options. The cause performed truthful well, successful fact, that the company's looking for somewhat peculiar regulatory attraction of mitapivat erstwhile utilized for this peculiar purpose.
The FDA's accelerated cause support process is designed to bring much urgently needed treatments to the marketplace sooner than they'd usually go available. Although this pathway doesn't warrant approval, it does underscore the FDA's perceived request for much therapy options for a peculiar disease.
In airy of the FDA's proposal for satisfying the regulator's accustomed drug-approval requirements with lone an abbreviated "confirmatory trial," arsenic of 12:05 p.m. ET Tuesday shares of Agios Pharmaceuticals are up 21.7%.
The market's knee-jerk effect is understandable. This is bully news, peculiarly for a cause that's already approved for other, akin purposes without immoderate large information concerns. The underserved sickle compartment illness therapy marketplace presently worthy a small little than $4 cardinal per twelvemonth could turn to much than $14 cardinal per twelvemonth by 2034, according to an outlook from Precedence Research. It conscionable needs much effectual treatments. Mitapivat could beryllium 1 of them, expanding the market's size simply by moving good capable to prescribe much often.
English (CA) · 
English (US) · 
Spanish (MX) ·